XML 109 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Other Financial Data - Earnings Per Common Share (Details)
$ / shares in Units, shares in Millions
3 Months Ended 12 Months Ended
Sep. 05, 2019
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
$ / shares
Sep. 28, 2019
USD ($)
$ / shares
Jun. 29, 2019
USD ($)
$ / shares
Mar. 30, 2019
USD ($)
$ / shares
Dec. 31, 2018
USD ($)
$ / shares
Sep. 29, 2018
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
$ / shares
Mar. 31, 2018
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2015
USD ($)
Aug. 25, 2015
Basic earnings per common share:                            
Earnings (loss) | $   $ 244,000,000 $ 267,000,000 $ 207,000,000 $ 151,000,000 $ 423,000,000 $ 247,000,000 $ 180,000,000 $ 117,000,000 $ 868,000,000 $ 966,000,000 $ (155,000,000)    
Weighted average common shares outstanding (in shares)                   166.6 162.4 162.9    
Per share amount (US$ per share) | $ / shares   $ 1.43 $ 1.60 $ 1.25 $ 0.92 $ 2.58 $ 1.52 $ 1.11 $ 0.73 $ 5.21 $ 5.95 $ (0.95)    
Diluted earnings per common share:                            
Earnings (loss) | $   $ 244,000,000 $ 267,000,000 $ 207,000,000 $ 151,000,000 $ 423,000,000 $ 247,000,000 $ 180,000,000 $ 117,000,000 $ 868,000,000 $ 966,000,000 $ (155,000,000)    
Weighted average common shares outstanding (in shares)                   166.6 162.4 162.9    
Add effect of dilutive securities:                            
Share-based awards (in shares)                   4.7 4.2 0.0    
Diluted weighted average common shares outstanding (in shares)                   175.6 172.0 162.9    
Per share amount (US$ per share) | $ / shares   $ 1.39 $ 1.51 $ 1.18 $ 0.86 $ 2.44 $ 1.43 $ 1.05 $ 0.69 $ 4.95 $ 5.62 $ (0.95)    
2.0% senior convertible notes due 2020                            
Add effect of dilutive securities:                            
Senior Convertible Notes (in shares)                   4.3 5.4 0.0    
1.75% senior convertible notes due 2024                            
Add effect of dilutive securities:                            
Senior Convertible Notes (in shares)                   0.0 0.0 0.0    
Convertible Debt | 2.0% senior convertible notes due 2020                            
Add effect of dilutive securities:                            
Debt instrument face principal amount | $ $ 800,000,000                       $ 1,000,000,000.0  
Debt instrument stated interest rate                         2.00% 2.00%
Convertible debt conversion ratio     0.0149186                      
Convertible debt conversion price (US$ per share) | $ / shares     $ 67.03                      
Convertible Debt | 1.75% senior convertible notes due 2024                            
Add effect of dilutive securities:                            
Debt instrument face principal amount | $ $ 1,000,000,000.0                          
Debt instrument stated interest rate 1.75%                          
Convertible debt conversion ratio 0.0049140                          
Convertible debt conversion price (US$ per share) | $ / shares $ 203.50                          
Stock Options                            
Add effect of dilutive securities:                            
Stock options excluded from computation of dilutive shares due to antidilutive nature (in shares)                   0.3 0.8 8.7    
Performance Options                            
Add effect of dilutive securities:                            
Stock options excluded from computation of dilutive shares due to antidilutive nature (in shares)                   0.1 0.6      
RSU's                            
Add effect of dilutive securities:                            
Stock options excluded from computation of dilutive shares due to antidilutive nature (in shares)                       1.4    
Convertible Debt Securities                            
Add effect of dilutive securities:                            
Stock options excluded from computation of dilutive shares due to antidilutive nature (in shares)                       3.1